Examination of barriers and barrier alteration in transscleral iontophoresis

Journal of Pharmaceutical Sciences

Volumn 97, Issue 2, 2008, Pages 831-844

  Molokhia, Sarah A ^a   Jeong, Eun Kee ^b   Higuchi, William I ^a   Li, S Kevin ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Drug delivery; Iontophoresis; MRI; Ocular; Transscleral

Indexed keywords

EDETIC ACID; MANGANESE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ELECTRIC FIELD; IN VITRO STUDY; IN VIVO STUDY; IONTOPHORESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RABBIT; SCLERA;

EID: 39749110836     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21003     Document Type: Article

References (38)

1. Yoo SH, Dursun D, Dubovy S, Miller D, Alfonso E, Forster RK, Behar-Cohen FF, Parel JM. 2002. Iontophoresis for the treatment of paecilomyces keratitis. Cornea 21:131-132.
2. Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ. 2005. Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release 106:386-390.
3. Behar-Cohen FF, Parel JM, Pouliquen Y, Thillaye-Goldenberg B, Goureau O, Heydolph S, Courtois Y, De Kozak Y. 1997. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res 65:533-545.
4. Lam TT, Edward DP, Zhu XA, Tso MO. 1989. Transscleral iontophoresis of dexamethasone. Arch Ophthalmol 107:1368-1371.
5. Behar-Cohen FF, El Aouni A, Gautier S, David G, Davis J, Chapon P, Parel JM. 2002. Transscleral coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: Influence of duration of treatment, current intensity, and drug concentration on ocular tissue and fluid levels. Exp Eye Res 74:51-59.
6. Voigt M, Kralinger M, Kieselbach G, Chapon P, Anagnoste S, Hayden B, Parel JM. 2002. Ocular aspirin distribution: A comparison of intravenous, topical, and coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci 43:3299-3306.
7. Parkinson TM, Ferguson E, Febbraro S, Bakhtyari A, King M, Mundasad M. 2003. Tolerance of ocular iontophoresis in healthy volunteers. J Ocul Pharmacol Ther 19:145-151.
8. Hughes L, Maurice DM. 1984. A fresh look at iontophoresis. Arch Ophthalmol 102:1825-1829.
9. Eljarrat-Binstock E, Domb AJ. 2006. Iontophoresis: A noninvasive ocular drug delivery. J Control Release 110:479-489.
10. Li SK, Zhang Y, Zhu H, Higuchi WI, White HS. 2005. Influence of asymmetric donor-receiver ion concentration upon transscleral iontophoretic transport. J Pharm Sci 94:847-860.
11. Kasting GB. 1992. Theoretical models for iontophoretic delivery. Adv Drug Deliv Rev 9:177-199.
12. Peck KD, Srinivasan V, Li SK, Higuchi WI, Ghanem AH. 1996. Quantitative description of the effect of molecular size upon electroosmotic flux enhancement during iontophoresis for a synthetic membrane and human epidermal membrane. J Pharm Sci 85:781-788.
13. Pikal MJ. 1992. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Del Rev 9:201-237.
14. Chizmadzhev YA, Indenbom AV, Kuzmin PI, Galichenko SV, Weaver JC, Potts RO. 1998. Electrical properties of skin at moderate voltages: Contribution of appendageal macropores. Biophys J 74:843-856.
15. Li SK, Ghanem A-H, Peck KD, Higuchi WI. 1999. Pore induction in human epidermal membrane during low to moderate voltage iontophoresis: A study using AC iontophoresis. J Pharm Sci 88:419-427.
16. Glaser RW, Leikin SL, Chernomordik LV, Pastushenko VF, Sokirko AI. 1988. Reversible electrical break-down of lipid bilayers: Formation and evolution of pores. Biochim Biophys Acta 940:275-287.
17. Chen C, Smye SW, Robinson MP, Evans JA. 2006. Membrane electroporation theories: A review. Med Biol Eng Comput 44:5-14.
18. Maurice DM. 1986. Iontophoresis of fluorescein into the posterior segment of the rabbit eye. Ophthalmology 93:128-132.
19. Kralinger MT, Voigt M, Kieselbach GF, Hamasaki D, Hayden BC, Parel JM. 2003. Ocular delivery of acetylsalicylic acid by repetitive coulomb-controlled iontophoresis. Ophthalmic Res 35:102-110.
20. Li SK, Molokhia SA, Jeong EK. 2004. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res 21:2175-2184.
21. Li SK, Jeong EK, Hastings MS. 2004. Magnetic resonance imaging study of current and ion delivery into the eye during transscleral and transcorneal iontophoresis. Invest Ophthalmol Vis Sci 45:1224-1231.
22. Molokhia SA, Jeong E-K, Higuchi WI, Li SK. 2007. Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging. Int J Pharm 335:46-53.
23. 2+. Magn Reson Med 8:293-313.
24. Berkowitz BA, Roberts R, Goebel DJ, Luan H. 2006. Noninvasive and simultaneous imaging of layer-specific retinal functional adaptation by manganese-enhanced MRI. Invest Ophthalmol Vis Sci 47:2668-2674.
25. Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, Wang NS, Csaky KG. 2004. Controlled drug release from an ocular implant: An evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 45: 2722-2731.
26. Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, Bungay PM, Yuan P, Wang NS, Kim J, Csaky KG. 2006. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 82:479-487.
27. Noske W, Stamm CC, Hirsch M. 1994. Tight junctions of the human ciliary epithelium: Regional morphology and implications on transepithelial resistance. Exp Eye Res 59:141-149.
28. Cunha-Vaz J. 1979. The blood-ocular barriers. Surv Ophthalmol 23:279-296.
29. Raghava S, Hammond M, Kompella UB. 2004. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 1:99-114.
30. Li SK, Zhu H, Higuchi WI. 2006. Enhanced transscleral iontophoretic transport with ion-exchange membrane. Pharm Res 23:1857-1867.
31. Ghate D, Edelhauser HF. 2006. Ocular drug delivery. Expert Opin Drug Deliv 3:275-287.
32. Andrieu-Soler C, Doat M, Halhal M, Keller N, Jonet L, BenEzra D, Behar-Cohen F. 2006. Enhanced oligonucleotide delivery to mouse retinal cells using iontophoresis. Mol Vis 12:1098-1107.
33. Blair-Parks K, Weston BC, Dean DA. 2002. High-level gene transfer to the cornea using electroporation. J Gene Med 4:92-100.
34. Andrieu-Soler C, Bejjani RA, de Bizemont T, Normand N, BenEzra D, Behar-Cohen F. 2006. Ocular gene therapy: A review of nonviral strategies. Mol Vis 12:1334-1347.
35. Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J. 2003. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 44:2141-2146.
36. Sander B, Larsen M, Moldow B, Lund-Andersen H. 2001. Diabetic macular edema: Passive and active transport of fluorescein through the blood-retina barrier. Invest Ophthalmol Vis Sci 42:433-438.
37. Lee TW, Robinson JR. 2004. Drug delivery to the posterior segment of the eye II: Development and validation of a simple pharmacokinetic model for subconjunctival injection. J Ocul Pharmacol Ther 20:43-53.
38. Wu JC, Jesmanowicz A, Hyde JS. 1992. Anterior segment high resolution MRI: Aqueous humor dynamics observed using contrast agents. Exp Eye Res 54:145-148.